CN104623633A - 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 - Google Patents

用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 Download PDF

Info

Publication number
CN104623633A
CN104623633A CN201510010273.9A CN201510010273A CN104623633A CN 104623633 A CN104623633 A CN 104623633A CN 201510010273 A CN201510010273 A CN 201510010273A CN 104623633 A CN104623633 A CN 104623633A
Authority
CN
China
Prior art keywords
days
neuregulin
hours
nrg
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510010273.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡加诺
A·甘谷利
J·艾希
T·帕利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CN104623633A publication Critical patent/CN104623633A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201510010273.9A 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 Pending CN104623633A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
US61/135,171 2008-07-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801360798A Division CN102159236A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Publications (1)

Publication Number Publication Date
CN104623633A true CN104623633A (zh) 2015-05-20

Family

ID=42005671

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510010273.9A Pending CN104623633A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN2009801360798A Pending CN102159236A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN201710109733.2A Expired - Fee Related CN107019794B (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2009801360798A Pending CN102159236A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN201710109733.2A Expired - Fee Related CN107019794B (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Country Status (13)

Country Link
US (5) US20110166068A1 (cg-RX-API-DMAC7.html)
EP (3) EP3338791B1 (cg-RX-API-DMAC7.html)
JP (5) JP5797112B2 (cg-RX-API-DMAC7.html)
CN (3) CN104623633A (cg-RX-API-DMAC7.html)
AU (3) AU2009292216B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916442A2 (cg-RX-API-DMAC7.html)
CA (1) CA2731113A1 (cg-RX-API-DMAC7.html)
DK (2) DK2320933T3 (cg-RX-API-DMAC7.html)
ES (2) ES2664394T3 (cg-RX-API-DMAC7.html)
MX (2) MX384378B (cg-RX-API-DMAC7.html)
PL (2) PL3338791T3 (cg-RX-API-DMAC7.html)
RU (4) RU2536938C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010030317A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778315A (zh) * 2016-04-19 2018-11-09 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) 用于治疗和/或预防神经系统肿瘤的神经调节素
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
WO2021052277A1 (zh) * 2019-09-16 2021-03-25 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013149163A1 (en) * 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3353546A1 (en) 2015-09-25 2018-08-01 Douglas B. Sawyer Methods for treating cardiac injury
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
WO2001034174A2 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2005525317A (ja) 2002-01-18 2005-08-25 カイロン コーポレイション Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070010518A1 (en) * 2005-02-18 2007-01-11 Matti Kivikko Method for administering levosimendan
MX2007010603A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013149163A1 (en) 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D HARARI1等: "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor", 《ONCOGENE》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778315A (zh) * 2016-04-19 2018-11-09 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) 用于治疗和/或预防神经系统肿瘤的神经调节素
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
WO2021052277A1 (zh) * 2019-09-16 2021-03-25 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
AU2020348436B2 (en) * 2019-09-16 2026-07-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof

Also Published As

Publication number Publication date
EP3338791B1 (en) 2019-09-18
RU2536938C2 (ru) 2014-12-27
AU2017203528A1 (en) 2017-06-15
CN107019794B (zh) 2021-03-12
ES2763184T3 (es) 2020-05-27
US20110166068A1 (en) 2011-07-07
US20200009228A1 (en) 2020-01-09
JP2011528353A (ja) 2011-11-17
EP2320933A1 (en) 2011-05-18
WO2010030317A2 (en) 2010-03-18
JP6189879B2 (ja) 2017-08-30
JP2015129137A (ja) 2015-07-16
US20160113999A1 (en) 2016-04-28
CA2731113A1 (en) 2010-03-18
CN102159236A (zh) 2011-08-17
JP5797112B2 (ja) 2015-10-21
PL3338791T3 (pl) 2020-04-30
JP2019196370A (ja) 2019-11-14
AU2009292216B2 (en) 2015-03-05
AU2009292216A1 (en) 2010-03-18
RU2020111236A3 (cg-RX-API-DMAC7.html) 2021-09-21
CN107019794A (zh) 2017-08-08
DK2320933T3 (en) 2018-04-16
RU2719199C1 (ru) 2020-04-17
PL2320933T3 (pl) 2018-07-31
EP2320933A4 (en) 2013-02-27
BRPI0916442A2 (pt) 2018-06-19
AU2015202877A1 (en) 2015-06-18
RU2020111236A (ru) 2021-09-21
RU2011105821A (ru) 2012-08-27
EP3632459A1 (en) 2020-04-08
US9198951B2 (en) 2015-12-01
JP2022023208A (ja) 2022-02-07
US11235031B2 (en) 2022-02-01
ES2664394T3 (es) 2018-04-19
EP2320933B1 (en) 2017-12-27
EP3338791A1 (en) 2018-06-27
US20130324466A1 (en) 2013-12-05
US20180280477A1 (en) 2018-10-04
MX384378B (es) 2025-03-14
RU2698090C2 (ru) 2019-08-22
RU2014141514A (ru) 2016-05-10
MX2011000696A (es) 2011-07-29
AU2015202877B2 (en) 2017-03-09
JP2017200949A (ja) 2017-11-09
HK1256637A1 (en) 2019-09-27
US9956266B2 (en) 2018-05-01
DK3338791T3 (da) 2019-12-16

Similar Documents

Publication Publication Date Title
US11235031B2 (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
AU2020204070B2 (en) Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
HK1241715B (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK40015761A (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1256637B (en) Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
HK1241715A1 (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1157181A (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1157181B (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150520